Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood [4]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2351-2353

  Cruden, N L M ^a,b   Lawes, L ^a   Masson, P ^a   Robinson, S D ^a   Ludlam, C A ^a   Newby, D E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; PLACEBO; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CIRCULATION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; NONHUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOGENESIS;

ADULT; CARBOXYPEPTIDASE U; FIBRINOLYSIS; HUMANS; MALE; PLANT PROTEINS; THROMBELASTOGRAPHY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 28444447030     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01600.x     Document Type: Letter

References (18)

1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
2. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
3. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
4. Guimaraes AH, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost 2004; 91: 473-9.
5. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
6. Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 661-6.
7. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
8. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
9. Summaria L. Thromboelastographic study of fibrinolytic agents. Semin Thromb Hemost 1995; 21(Suppl. 4): 63-71.
10. D'Amico EA, Chamone DA, Bydlowski SP. In vitro effects of rt-PA on platelet function and clot strength. Thromb Res 1997; 85: 519-22.
11. Fox KA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1985; 72: 1346-54.
12. Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost 2002; 88: 282-7.
13. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
14. Genser N, Lechleitner P, Maier J, Dienstl F, Artner-Dworzak E, Puschendorf B, Mair J. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem 1998; 44: 209-14.
15. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
16. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525-8.
17. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99: 1411-5.
18. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103: 1936-41.